| 000 | 01792 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515152210.0 | ||
| 264 | 0 | _c20090224 | |
| 008 | 200902s 0 0 eng d | ||
| 022 | _a1019-6439 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSebens Müerköster, Susanne | |
| 245 | 0 | 0 |
_aalpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. _h[electronic resource] |
| 260 |
_bInternational journal of oncology _cJan 2009 |
||
| 300 |
_a243-53 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xtherapeutic use |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCarcinoma, Pancreatic Ductal _xdrug therapy |
| 650 | 0 | 4 |
_aCaspases _xmetabolism |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEtoposide _xtherapeutic use |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntegrin alpha5 _xphysiology |
| 650 | 0 | 4 | _aMutagenesis, Site-Directed |
| 650 | 0 | 4 |
_aNeural Cell Adhesion Molecule L1 _xgenetics |
| 650 | 0 | 4 |
_aNitric Oxide Synthase Type II _xmetabolism |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 |
_aRNA, Small Interfering _xpharmacology |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 | _aTransfection |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aKötteritzsch, Jörn | |
| 700 | 1 | _aGeismann, Claudia | |
| 700 | 1 | _aGast, Daniela | |
| 700 | 1 | _aKruse, Marie-Luise | |
| 700 | 1 | _aAltevogt, Peter | |
| 700 | 1 | _aFölsch, Ulrich R | |
| 700 | 1 | _aSchäfer, Heiner | |
| 773 | 0 |
_tInternational journal of oncology _gvol. 34 _gno. 1 _gp. 243-53 |
|
| 999 |
_c18534609 _d18534609 |
||